| Upgrades | Neutral Outperform | X | ||
| Downgrades | Outperform Neutral | X | ||
|
$9 $2.50 |
||||
| Downgrades | Buy Hold | X | ||
| Downgrades | Neutral Underperform | X | ||
|
$9 $1 |
||||
| Reiterated | Buy | X | ||
|
$35 $7 |
||||
| Downgrades | Eq-Weight Underweight | X | ||
|
$10 $3 |
||||
| Upgrades | Hold Buy | X | ||
|
$8 $15 |
||||
| Initiated | Buy | X | ||
| Initiated | Overweight | X | ||
| Downgrades | Buy Neutral | X | ||
|
$24 $12 |
||||
| Downgrades | Overweight Eq-Weight | X | ||
|
$27 $13 |
||||
| Initiated | Buy | X | ||
| Initiated | Sell | X | ||
| Downgrades | Buy Hold | X | ||
|
$32 $18 |
||||
| Resumed | Buy | X | ||
| Initiated | Overweight | X | ||
| Initiated | Buy | X | ||
| Initiated | Overweight | X | ||
| Initiated | Outperform | X | ||
ALEC Alector, Inc.
Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ
Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of Alzheimer's and Parkinson's diseases; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under preclinical research stage. The company was founded in 2013 and is headquartered in South San Francisco, California.
